Novo Nordisk Reports Insider Trading Activities
This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives, and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives, and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives, and their associated persons.
Details of the Board Members and Executives
Please find below a statement of such trading in shares issued by Novo Nordisk.
Information on Transactions
Details of the person discharging managerial responsibilities/person closely associated: Sylvie Louise Grégoire, Member of the Board of Directors. Initial notification.
Details of the issuer: Novo Nordisk A/S, LEI: 549300DAQ1CVT6CXN342.
Details of the transaction(s): Description of the financial instrument: ADRs (Identification code: NVO). Nature of the transaction: Purchase of ADRs.
Aggregated Information
Aggregated volume: 1,500 ADRs. Price: DKK 1,368,944.39.
Date of the transaction: 2024-08-19. Place of the transaction: New York Stock Exchange.
Company Overview
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Its purpose is to drive change to defeat serious chronic diseases, built upon a heritage in diabetes. The company pioneers scientific breakthroughs, expands access to medicines, and works to prevent and ultimately cure diseases. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B), and its ADRs are listed on the New York Stock Exchange (NVO).
Contact Information
Media Contacts:
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
Investor Contacts:
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com
Frequently Asked Questions
What transactions are disclosed in this announcement?
The announcement discloses transactions made in Novo Nordisk shares by board members and executives.
Who is the person mentioned in the announcement?
Sylvie Louise Grégoire is identified as a member of the Board of Directors.
What is the purpose of this disclosure?
This disclosure is made in compliance with Article 19 of Regulation No. 596/2014 on market abuse.
What type of shares were involved in the transactions?
The transactions involved American Depositary Receipts (ADRs).
How can I contact Novo Nordisk for more information?
You can reach media or investor relations contacts provided in the announcement for additional information.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.